Saudi Pharmaceutical Industries and Medical Appliances Corporation (2070) Fair Value & Analysis
Healthcare · SA · Market cap 3.8B SAR
Fair value as of: Jul 31, 2026
From 24 valuation models · updated 10 days ago
Share price +10.8% over the past month.
A solid business, but screening 22% overvalued on our models.
What matters now
- Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (15.51 SAR to 36.16 SAR) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.
How to read this chart
60‑month range 21.16 SAR – 58.61 SAR · fair‑value band 15.51 SAR – 36.16 SAR · the 31.30 SAR price screens above the 24.52 SAR fair value. Dashed = 300-day average. As of Jul 31, 2026.
Analysis
Saudi Pharmaceutical Industries and Medical Appliances Corporation (2070) currently trades at 31.30 SAR, while our model-based Fair Value estimate is 24.52 SAR, implying the stock looks roughly 21.7% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Saudi Pharmaceutical Industries and Medical Appliances Corporation generated revenue of 1.6B SAR at a net margin of 10.9%. Revenue declined 12.6% year over year. It earns a return on equity of 11.0%. Net debt stands at 1.2B SAR. Fundamentals as of Jul 31, 2026
Our scenario range runs from 15.51 SAR (bear case) to 36.16 SAR (bull case); at 31.30 SAR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 4% below its 52-week high and 27% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -22%, 2070 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Multiples (26.83 SAR) versus Dividend Discount (0.2800 SAR). Highest evidence: Growth DCF (80).
Notify me when 2070 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 64
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Saudi Pharmaceutical Industries and Medical Appliances Corporation develops, manufactures, and markets medicinal and pharmaceutical products in the Kingdom of Saudi Arabia, the Middle East, Egypt, Algeria, and Morocco. The company operates through Pharmaceutical Manufacturing, Trading and Distribution Services, and Healthcare Services segments.
Full company description
Saudi Pharmaceutical Industries and Medical Appliances Corporation develops, manufactures, and markets medicinal and pharmaceutical products in the Kingdom of Saudi Arabia, the Middle East, Egypt, Algeria, and Morocco. The company operates through Pharmaceutical Manufacturing, Trading and Distribution Services, and Healthcare Services segments. The company is involved in the sale, marketing, and distribution of pharmaceutical, veterinary, medical equipment, and cosmetics products; and operates and maintains a secondary care hospital. In addition, it manufactures human medicines, and wholesales and retails of medicines and related products. Further, the company engages in the research and development of medical science activities, and investment business in related industries. The company was incorporated in 1986 and is headquartered in Buraydah, the Kingdom of Saudi Arabia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Saudi Pharmaceutical Industries and Medical Appliances Corporation reported revenue of 1.7B SAR in FY2025 versus 1.5B SAR in FY2021, a compound +4.0%/yr. Reported net income was 184M SAR in FY2025, compounding +62.5%/yr from FY2021.
2070 screens 22% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Saudi Pharmaceutical Industries and Medical Appliances Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Saudi Pharmaceutical Industries and Medical Appliances Corporation (2070) overvalued or undervalued?
What is the fair value of 2070?
What is the quality score of 2070?
What is the revenue of Saudi Pharmaceutical Industries and Medical Appliances Corporation (2070)?
What is the net profit margin of 2070?
Does Saudi Pharmaceutical Industries and Medical Appliances Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Saudi Pharmaceutical Industries and Medical Appliances Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.